Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 3:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 8,035 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: RNA Clear all
Completed Phase 2 Interventional

An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant

NCT02165189
View directory record Official record
Conditions
Hepatitits C
Interventions
Simeprevir, Sofosbuvir, Ribavirin
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Aurora, Colorado • Gainesville, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2016 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Not applicable Interventional

Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy

NCT00038259
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Phase 3 Interventional Results available

PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C

NCT00100659
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Pegylated Interferon/ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
5 Years to 18 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Phase 4 Interventional Results available

Study of Long-term Peg Intron vs. Colchicine in Non-responders.

NCT00179413
View directory record Official record
Conditions
Hepatitis C Virus, Advanced Fibrosis, Cirrhosis
Interventions
PEG -Intron, Colchicine
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Phase 3 Interventional

A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past

NCT00002320
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
12 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • Sherman Oaks, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2005 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cell Mediated Immunity in Older Adults

NCT01189123
View directory record Official record
Conditions
Immunity to Influenza Vaccine
Interventions
High dose influenza vaccine Sanofi-Pasteur, fluzone by sanofi pasteur
Biological
Lead sponsor
Vanderbilt University
Other
Eligibility
65 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 25, 2026, 3:15 PM EDT
Withdrawn Phase 4 Interventional

Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant

NCT03026023
View directory record Official record
Conditions
Cardiac Transplant Disorder, Hepatitis C
Interventions
Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin
Drug
Lead sponsor
Raymond T. Chung, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 25, 2026, 3:15 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age

NCT07851246
View directory record Official record
Conditions
Influenza, Human
Interventions
mRNA Seasonal Flu vaccine, Comparator 1, Comparator 2
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
12
States / cities
Glendale, Arizona • Tucson, Arizona • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Phase 2 Interventional

A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3

NCT00000625
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
56
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mail Outreach To Increase Vaccination Acceptance Through Engagement

NCT02243774
View directory record Official record
Conditions
Influenza, Human, Influenza, Human Flu
Interventions
Core letter signed by Surgeon General, Core letter signed by the Director of the National Vaccine Program, Core letter signed by Surgeon General + implementation prompt, Core letter signed by SG + enhanced implementation prompt
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
66 Years and older
Enrollment
228,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 25, 2026, 3:15 PM EDT
Not listed Not applicable Interventional

Natural History of COVID-19-Related Atrial Fibrillation

NCT04830774
View directory record Official record
Conditions
COVID-19, Atrial Fibrillation New Onset
Interventions
ILR, PMK, ICD
Device
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Kansas City, Kansas • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Not applicable Interventional

Rural PrEP Delivery

NCT03343223
View directory record Official record
Conditions
HIV/AIDS
Interventions
Intervention Group
Behavioral
Lead sponsor
Michael Ohl
Other
Eligibility
18 Years to 70 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Oct 25, 2026, 3:15 PM EDT
Recruiting Phase 4 Interventional

Menopausal HT for Women Living With HIV (HoT)

NCT06856174
View directory record Official record
Conditions
HIV Infection, Menopause
Interventions
Transdermal estradiol gel, Micronized Progesterone, Placebo for estradiol gel, Placebo for micronized progesterone
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
40 Years to 60 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Phase 2 Interventional

A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain

NCT00002160
View directory record Official record
Conditions
HIV Infections, Cancer, Pain
Interventions
Ziconotide
Drug
Lead sponsor
Neurex
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Huntsville, Alabama • Mobile, Alabama • Northport, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Not applicable Interventional

A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell

NCT00002323
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Oakland, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 3:15 PM EDT
Not listed Phase 2 Interventional

Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

NCT04840459
View directory record Official record
Conditions
Covid19
Interventions
BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB
Biological
Lead sponsor
Sohail Rao
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Edinburg, Texas • Rio Grande City, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

NCT00000989
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Zidovudine, Sargramostim, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 25, 2026, 3:15 PM EDT
Completed No phase listed Observational

A Comparison of Two Tests for Anti-HIV Drug Resistance

NCT00006490
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
46
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Phase 2 Interventional

A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection

NCT00000823
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
22
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children

NCT02539108
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent Influenza Vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 8 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 25, 2026, 3:15 PM EDT
Terminated No phase listed Observational

Clinical Performance Evaluation of DxN HCV Assay

NCT03125408
View directory record Official record
Conditions
Hepatitis C
Interventions
HCV Assay
Diagnostic Test
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Duluth, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C

NCT00118768
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
valopicitabine, Pegylated Interferon Alfa
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
175 participants
Timeline
Started 2005
U.S. locations
19
States / cities
Phoenix, Arizona • San Diego, California • San Mateo, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2009 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of a Combined Nature-based and Virtual Mindfulness Intervention on Perceived Stress in Healthcare Workers

NCT04846790
View directory record Official record
Conditions
Stress, Psychological, Sleep Disturbance, Burnout, Caregiver, Posttraumatic Stress Disorder, Anxiety, Depression
Interventions
Nature Only, Nature+Mindfulness
Behavioral
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance

NCT04459520
View directory record Official record
Conditions
COVID-19
Interventions
Positive COVID Test Result - Hypothetical Scenario, Negative COVID Test Result - Hypothetical Scenario, Unavailable COVID Test Result - Hypothetical Scenario
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 110 Years
Enrollment
1,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 25, 2026, 3:15 PM EDT